Logo image of AMIX

AUTONOMIX MEDICAL INC (AMIX) Stock Fundamental Analysis

NASDAQ:AMIX - Nasdaq - US05330T2050 - Common Stock - Currency: USD

2.18  -0.11 (-4.8%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AMIX. AMIX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. AMIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AMIX had negative earnings in the past year.
AMIX had a negative operating cash flow in the past year.
AMIX Yearly Net Income VS EBIT VS OCF VS FCFAMIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M

1.2 Ratios

AMIX's Return On Assets of -114.01% is on the low side compared to the rest of the industry. AMIX is outperformed by 83.60% of its industry peers.
Looking at the Return On Equity, with a value of -140.37%, AMIX is doing worse than 67.20% of the companies in the same industry.
Industry RankSector Rank
ROA -114.01%
ROE -140.37%
ROIC N/A
ROA(3y)-339.93%
ROA(5y)N/A
ROE(3y)-388.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMIX Yearly ROA, ROE, ROICAMIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMIX Yearly Profit, Operating, Gross MarginsAMIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

AMIX has less shares outstanding than it did 1 year ago.
AMIX has a worse debt/assets ratio than last year.
AMIX Yearly Shares OutstandingAMIX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
AMIX Yearly Total Debt VS Total AssetsAMIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -6.02, we must say that AMIX is in the distress zone and has some risk of bankruptcy.
AMIX's Altman-Z score of -6.02 is on the low side compared to the rest of the industry. AMIX is outperformed by 70.90% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that AMIX is not too dependend on debt financing.
AMIX has a Debt to Equity ratio (0.12) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z -6.02
ROIC/WACCN/A
WACCN/A
AMIX Yearly LT Debt VS Equity VS FCFAMIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M

2.3 Liquidity

AMIX has a Current Ratio of 5.31. This indicates that AMIX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AMIX (5.31) is better than 78.31% of its industry peers.
A Quick Ratio of 5.31 indicates that AMIX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.31, AMIX belongs to the best of the industry, outperforming 82.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.31
Quick Ratio 5.31
AMIX Yearly Current Assets VS Current LiabilitesAMIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

AMIX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18089.44%.
EPS 1Y (TTM)-18089.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.95% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.15%
EPS Next 2Y29.41%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMIX Yearly EPS VS EstimatesAMIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMIX. In the last year negative earnings were reported.
Also next year AMIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMIX Price Earnings VS Forward Price EarningsAMIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMIX Per share dataAMIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as AMIX's earnings are expected to grow with 18.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.41%
EPS Next 3Y18.95%

More info and screens

0

5. Dividend

5.1 Amount

AMIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUTONOMIX MEDICAL INC

NASDAQ:AMIX (5/2/2025, 10:38:01 AM)

2.18

-0.11 (-4.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)N/A N/A
Inst Owners19.88%
Inst Owner Change0%
Ins Owners14.62%
Ins Owner Change0%
Market Cap5.36M
Analysts85.71
Price Target18.36 (742.2%)
Short Float %4.13%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)45%
EPS NY rev (1m)0%
EPS NY rev (3m)80.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-12.53
EYN/A
EPS(NY)-5.32
Fwd EYN/A
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.27
OCFYN/A
SpS0
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.01%
ROE -140.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-339.93%
ROA(5y)N/A
ROE(3y)-388.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.31
Quick Ratio 5.31
Altman-Z -6.02
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18089.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.33%
EPS Next Y91.15%
EPS Next 2Y29.41%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-504.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-259.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.5%
OCF growth 3YN/A
OCF growth 5YN/A